GH Research (FRA:1KA) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


FRA:1KA GH Research PLC FRA:1KA
35 GF Score
Price €21.20
! 2 Warning Signs
View Full Analysis

What is GH Research Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

GH Research's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

FRA:1KA vs BHVN, NUVB, GLUE: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, GH Research's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GH Research Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GH Research's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where GH Research's Margin of Safety % (DCF FCF Based) falls into.


FRA:1KA
35GF Score
GH Research PLC FRA:1KA
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GH Research Business Description

Other Exchanges GHRS:USA
Address Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
35GF Score

Get the complete analysis for FRA:1KA

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.20
Price